Phase I clinical results with MLN518, a novel FLT3 antagonist: Tolerability, pharmacokinetics, and pharmacodynamics.

被引：0
|
作者：
De Angelo, DJ
Stone, RM
Bruner, RJ
Caligiuri, MA
Heaney, ML
Nimer, SD
Paquette, R
Sawyers, CL
Lambing, JL
Lokker, NA
Giese, NA
Sinha, V
Cooper, MR
Druker, BJ
Heinrich, MC
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Comprehens Canc Ctr, Columbus, OH USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Univ Calif Los Angeles, Ctr Med, Los Angeles, CA 90024 USA
[5] Millennium Pharmaceut Inc, Cambridge, MA USA
[6] Oregon Hlth Sci Univ, Portland, OR USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
219
引用
收藏
页码：65A / 66A
页数：2
相关论文
共 50 条
  • [1] Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics
    DeAngelo, Daniel J.
    Stone, Richard M.
    Heaney, Mark L.
    Nimer, Stephen D.
    Paquette, Ronald L.
    Klisovic, Rebecca B.
    Caligiuri, Michael A.
    Cooper, Michael R.
    Lecerf, Jean-Michel
    Karol, Michael D.
    Sheng, Shihong
    Holford, Nick
    T Curtin, Peter
    Druker, Brian J.
    Heinrich, Michael C.
    BLOOD, 2006, 108 (12) : 3674 - 3681
  • [2] Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis
    Griswold, IJ
    Shen, LJ
    La Rosée, P
    Demehri, S
    Heinrich, MC
    Braziel, RM
    McGreevey, L
    Haley, AD
    Giese, N
    Druker, BJ
    Deininger, MWN
    BLOOD, 2004, 104 (09) : 2912 - 2918
  • [3] Mechanisms of cellular resistance to MLN518 (CTS3518), a FLT3 antagonist in clinical development for the treatment of acute myelogenous leukemia (AML).
    Yu, JC
    Apatira, M
    Li, J
    Sullivan, C
    Hwang, S
    Lokker, N
    Giese, NA
    BLOOD, 2003, 102 (11) : 591A - 591A
  • [4] MLN518, a potent FLT3 inhibitor, displays synergistic effects with cytarabine and daunorubicin on FLT3 ITD leukemia cell lines.
    Heinrich, MC
    Yee, KWH
    Giese, NA
    Schittenhelm, M
    BLOOD, 2003, 102 (11) : 97A - 97A
  • [5] Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518
    Clark, JJ
    Cools, J
    Curley, DP
    Yu, JC
    Lokker, NA
    Giese, NA
    Gilliland, DG
    BLOOD, 2004, 104 (09) : 2867 - 2872
  • [6] Effects of MLN518 (CT53518), a dual Flt3 and kit inhibitor, on normal and malignant hematopoiesis.
    Shen, J
    La Rosee, P
    Griswold, I
    Heinrich, MC
    Braziel, R
    McGreevey, L
    Haley, A
    Giese, N
    Druker, BJ
    Deininger, MW
    BLOOD, 2003, 102 (11) : 138A - 138A
  • [7] The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin
    Schittenhelm, Marcus M.
    Kampa, Kerstin M.
    Yee, Kevin W. H.
    Heinrich, Michael C.
    CELL CYCLE, 2009, 8 (16) : 2621 - 2630
  • [8] Tandutinib (MLN518), a potent FLT3 inhibitor, synergizes with cytarabine and/or daunorubicin in a sequence-independent manner.
    Schittenhelm, Marcus M.
    Yee, Kevin W.
    Kampa, Kerstin M.
    Heinrich, Michael C.
    BLOOD, 2006, 108 (11) : 401A - 401A
  • [9] Transcriptional profiling of FLT3 ITD-positive leukemia cells treated with the FLT3 antagonist MLN518 (CT53518) identifies signaling pathways mediating cellular proliferation and survival.
    Lokker, NA
    Sullivan, CM
    Yazar, B
    Iartchouk, N
    Hwang, S
    Giese, NA
    BLOOD, 2003, 102 (11) : 367A - 367A
  • [10] RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518
    Walters, DK
    Stoffregen, EP
    Heinrich, MC
    Deininger, MW
    Druker, BJ
    BLOOD, 2005, 105 (07) : 2952 - 2954
12345